Business Wire

MN-VÄRDE-PARTNERS

12.10.2020 13:02:13 CEST | Business Wire | Press release

Share
Värde Partners Bolsters Global Leadership With Appointments of President and Deputy CEO

Värde Partners, a leading global alternative investment firm, today announced the promotion of Jon Fox to the role of President and Andy Lenk to the role of Deputy CEO, effective immediately. These appointments are the latest in a series of transition steps which previously included the appointment of Ilfryn Carstairs as Co-CEO and CIO and the promotions of Brad Bauer and Giuseppe Naglieri as Deputy CIOs.

“I’ve often said that transition is a process involving the entire firm and a number of leaders,” said George Hicks, Co-Founder and Co-CEO. “The appointments reflect the many contributions of Jon and Andy to the success and growth of the firm as well as the leadership experience and capabilities that they will bring to the years ahead.” Previously announced in July 2019, George intends to move to an Executive Chair role at the end of 2021.

Ilfryn Carstairs added, “These promotions are an important step in ensuring that we have the right senior leadership team for the next chapter at Värde. I’ve worked very closely with Jon and Andy for many years and I’m excited to see this elevation in their roles.”

In addition to the President and Deputy CEO roles, Värde announced promotions and role changes within the areas of Financial Services, Insurance, and Capital Markets:

  • Elena Lieskovska, Partner, will head a new, dedicated Insurance business after leading this effort within the Financial Services team and previously leading specialty finance investing in Europe.
  • Aneek Mamik, Senior Managing Director, will be promoted to Global Co-Head of Financial Services from his current role leading those investments in North America and Asia. He will oversee the global team with Partner Rick Noel.
  • Craig Rydqvist, Senior Managing Director and Global Head of Capital Markets based in London, will join the Financial Services team to lead investments outside of North America.
  • Missy Dolski, Managing Director, will be promoted to Global Head of Capital Markets from her current role as Head of Capital Markets for North America.

Commenting on these appointments, Deputy CIO Brad Bauer said, “We’re excited to announce these promotions which align proven leadership talent with significant areas of opportunity for our investors. These individuals represent the breadth and depth of talent we have in our investing teams and these promotions are well deserved in light of their contributions.”

Jon Fox is a Partner and the head of the New York office who joined the firm in 2013 in London. He has led the firm’s global Business Development and Investor Relations team, fund and product development, and also oversees Communications and Public Affairs. He is a member of the firm’s Investment Committee and Senior Leadership Committee and plays an important role in general management decisions. In 2018, Jon relocated from London to become the head of the firm’s New York office. He will maintain all existing leadership responsibilities as President and further develop Värde’s global industry relationships.

Jon holds a B.A. from the University of Colorado, an M.B.A. from Columbia Business School and serves on the boards of trustees of the Fire Department of New York (FDNY) Foundation and Oliver Scholars and on the Business Council of the Asia Society.

Andy Lenk joined the firm in 2001 and is a Partner in Minneapolis. As Global Head of Strategy and Portfolio Operations, he works closely with the Co-CEOs on all aspects of firm strategy, finance, talent and operations. He is a member of the firm’s Investment Committee, Senior Leadership Committee and the Enterprise Risk Management Committee. Andy has held many leadership roles for the firm including oversight and development of global Portfolio Operations, Capital Markets, Asset Management and the firm’s Finance and Operations functions. Earlier in his career at Värde, Andy worked in investing teams in both the U.S. and Europe.

Andy received a B.B.A. in Accounting from the University of Wisconsin-Madison and an M.B.A. from the University of Michigan. He is a CPA (inactive).

About Värde Partners
Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested more than $75 billion since inception and manages over $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals worldwide with offices in Minneapolis, New York, London, Singapore and other cities in Asia and Europe. For more information, please visit www.varde.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye